Cecile Pages

Cecile Pages

Toulouse, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 75 publications

Update on dermatological toxicities of immune checkpoint inhibitors.

Update on dermatological toxicities of immune checkpoint inhibitors.

Journal: Presse medicale (Paris, France : 1983)

Published: September 08, 2025

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.

Journal: Nature medicine

Published: March 21, 2025

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: a nationwide real-life study in France (NEOMEL).

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: a nationwide real-life study in France (NEOMEL).

Journal: The British journal of dermatology

Published: December 10, 2024

The prognostic value of tumor-infiltrating lymphocytes in vulvovaginal melanoma.

The prognostic value of tumor-infiltrating lymphocytes in vulvovaginal melanoma.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: November 20, 2024

International survey on training of dermatology residents in supportive oncodermatology: the RESCUE study.

International survey on training of dermatology residents in supportive oncodermatology: the RESCUE study.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: November 05, 2024

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study.

TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study.

Journal: International journal of cancer

Published: September 19, 2024

Rare Immuno-Induced Keratoacanthomas Showed on 18F-FDG PET/CT in a Metastatic Melanoma Patient.

Rare Immuno-Induced Keratoacanthomas Showed on 18F-FDG PET/CT in a Metastatic Melanoma Patient.

Journal: Clinical nuclear medicine

Published: September 03, 2024

Atypical and/or systemic dermatologic disorders related to immune checkpoint inhibitors: A review

Atypical and/or systemic dermatologic disorders related to immune checkpoint inhibitors: A review

Journal: La Revue de medecine interne

Published: August 20, 2024

Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational study.

Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational study.

Journal: Cancer

Published: August 08, 2024

The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting.

The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting.

Journal: The British journal of dermatology

Published: July 17, 2024

High-Dose-Rate Brachytherapy for Treatment of Facial Skin Cancers: Local Control, Toxicity, and Quality of Life in 67 Patients.

High-Dose-Rate Brachytherapy for Treatment of Facial Skin Cancers: Local Control, Toxicity, and Quality of Life in 67 Patients.

Journal: Cancers

Published: June 13, 2024

Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial.

Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial.

Journal: Investigational new drugs

Published: June 07, 2024

Showing 1-12 of 75

Last Updated: 09/26/2026